Form 4: Harmony Biosciences Executive Dierks Sells 400 Shares

Jeffrey Dierks, Chief Commercial Officer of Harmony Biosciences Holdings, Inc., sold 400 shares of common stock on October 1, 2024, while also exercising options for 400 shares at $24.

Summary

• On October 1, 2024, Jeffrey Dierks, the Chief Commercial Officer of Harmony Biosciences Holdings, Inc., executed transactions involving the company's common stock.
• Dierks exercised stock options to acquire 400 shares at a price of $24 per share.
• Simultaneously, Dierks sold 400 shares of common stock at a weighted average price of $40.1923, with individual sales ranging from $40.01 to $40.45.
• Following these transactions, Dierks directly owns 0 shares of common stock and 50,468 derivative securities.
• The sale was conducted under a Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: Neutral sentiment as it reflects routine insider trading activity under a pre-arranged plan.

Industry Context

Form 4 filings are a routine part of the regulatory landscape, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares traded.

Key Dates